1: Karnik NS, Maldonado JR. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 2005 Nov-Dec;46(6):565-8. Review. PubMed PMID: 16288136.
2: Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002 Sep;14(3):175-82. Review. PubMed PMID: 12585567.
3: DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry. 2002;63 Suppl 1:10-7. Review. PubMed PMID: 11890560.
4: Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol. 1999 Aug;19(4):427-42. Review. PubMed PMID: 10379419.
5: Goldberg RJ. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs Aging. 1997 Aug;11(2):119-31. Review. PubMed PMID: 9259175.
6: Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. Review. PubMed PMID: 9098663.
7: Cyr M, Brown CS. Nefazodone: its place among antidepressants. Ann Pharmacother. 1996 Sep;30(9):1006-12. Review. PubMed PMID: 8876863.
8: Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm. 1995 Dec 15;52(24):2799-812. Review. PubMed PMID: 8748566.
9: Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. Review. PubMed PMID: 7649970.
10: Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56 Suppl 6:12-21. Review. PubMed PMID: 7649968.
11: Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol. 1993;16 Suppl 3:S45-50. Review. PubMed PMID: 8131154.
12: Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull. 1990;26(3):311-5. Review. PubMed PMID: 2274630.
13: Hales RE, Hilty DM, Brunson GH. Cost savings with nefazodone in treating depression. J Clin Psychiatry. 2002;63 Suppl 1:48-51. Review. PubMed PMID: 11890565.
14: Dunner DL, Laird LK, Zajecka J, Bailey L, Sussman N, Seabolt JL. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002;63 Suppl 1:32-41. Review. PubMed PMID: 11890563.
15: Schatzberg AF, Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW. Clinical use of nefazodone in major depression: a 6-year perspective. J Clin Psychiatry. 2002;63 Suppl 1:18-31. Review. PubMed PMID: 11890561.
16: Khouzam HR. The antidepressant nefazodone. A review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration. J Psychosoc Nurs Ment Health Serv. 2000 Aug;38(8):20-5. Review. PubMed PMID: 10959472.
17: Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998 Dec;51(3):237-54. Review. PubMed PMID: 10333980.
18: Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998;7 Suppl 1:24-32. Review. PubMed PMID: 9597349.
19: Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997 Oct;33(4):260-75. Review. PubMed PMID: 9342502.
20: Augustin BG, Cold JA, Jann MW. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy. 1997 May-Jun;17(3):511-30. Review. PubMed PMID: 9165554.